Avenue Therapeutics, Inc. - Common Stock (ATXI)
1.3400
-0.0200 (-1.47%)
Avenue Therapeutics Inc is a pharmaceutical company focused on the development of innovative therapies for the treatment of various medical conditions, primarily within the realm of pain management
The company is dedicated to advancing its pipeline of drug candidates, leveraging scientific research and clinical expertise to address unmet needs in healthcare. Avenue Therapeutics aims to bring new options to patients and healthcare providers, with a commitment to improving quality of life through its therapeutic solutions.
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 27, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 24, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 17, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 2, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/26/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 26, 2024
![](https://investorplace.com/wp-content/uploads/2022/09/atxi1600.png)
ATXI stock results show that Avenue Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024
![](https://investorplace.com/wp-content/uploads/2022/09/atxi1600.png)
ATXI stock results show that Avenue Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 15, 2024
![](/next-assets/images/schema-image-default.png)
Via Benzinga · April 29, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/29/vaccine-4892059.jpeg?width=1200&height=800&fit=crop)
Avenue Therapeutics shares are trading lower by 20.7% during Monday's session. The company announced the exercise of warrants for $4.4 million in gross proceeds.
Via Benzinga · April 29, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/26/Aon---logo.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · April 26, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/24/Stock-Market_3.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · April 24, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/24/Stock-Market-Data---chart-illustration_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · April 24, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/24/doctor-563429.jpeg?width=1200&height=800&fit=crop)
Avenue Therapeutics shares are trading lower by 28.5% during Wednesday's session. The company is implementing a 1-for-75 reverse stock split.
Via Benzinga · April 24, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · April 9, 2024
![](https://investorplace.com/wp-content/uploads/2022/09/atxi1600.png)
ATXI stock results show that Avenue Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 19, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 15, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/11/image16_0.jpg?width=1200&height=800&fit=crop)
Shares of Mesoblast Limited (NASDAQMESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.
Via Benzinga · March 11, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/11/image29.jpeg?width=1200&height=800&fit=crop)
Shares of Fangdd Network Group Ltd. (NASDAQDUO) rose sharply in today’s pre-market trading after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector. Fangdd Network Group shares jumped 78.3% to $1.08 in pre-market trading
Via Benzinga · March 11, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/05/image31.jpeg?width=1200&height=800&fit=crop)
Shares of Applied Therapeutics, Inc.
Via Benzinga · January 5, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 5, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/05/11.png?width=1200&height=800&fit=crop)
Avenue Therapeutics Inc (NASDAQATXI) shares are trading lower by 31% to $0.24 Friday morning after the company announced it has entered into warrant exercise agreements with existing
Via Benzinga · January 5, 2024